Sam J. Milanovich
Expertise in
3
conditions

Dr. Sam J. Milanovich

Hematology | Oncology
Sanford Broadway Medical Center
801 Broadway N., 
Fargo, ND 
Accepting New Patients
Expertise in
3
conditions
Sanford Broadway Medical Center
801 Broadway N., 
Fargo, ND 

Overview

Dr. Sam Milanovich treats cancer and blood disorders in children and young adults. He also conducts childhood cancer research where he focuses on understanding how blood cancers begin and the variations in the genetics of different cancers. He holds the following leadership roles: Listen to Dr. Sam Milanovich on Sanford Health’s Innovations podcast where he discusses personalized medicine treats kids’ cancers . Speaks: English.

Dr. Milanovich is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, Ependymoma, and Bone Marrow Aspiration.

Dr. Milanovich is board certified in American Board Of Pediatrics: Pediatric Hematology/Oncology American Board Of Pediatrics: Pediatrics. He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 28 clinical trials. Dr. Milanovich is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in SD

Board Certifications

American Board Of Pediatrics: Pediatric Hematology/Oncology American Board Of Pediatrics: Pediatrics

Fellowships

Medical College of Wisconsin/Blood Research Institute, Pediatric Hematology/Oncology

Hospital Affiliations

Sanford Medical Center Fargo
Sanford Usd Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

Sanford Broadway Medical Center
801 Broadway N., Fargo, ND 58102

Additional Areas of Focus

Dr. Milanovich has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
View 9 Less Clinical Trials

11 Total Publications

A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer.
A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer.
Journal: Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association
Published: December 27, 2024
Similar Doctors
Expertise in
47
conditions
Dr. Matthew J. Tinguely
Hematology | Oncology
Expertise in
47
conditions
Dr. Matthew J. Tinguely
Hematology | Oncology
Referral may be required

Sanford Roger Maris Cancer Center

820 Fourth St. N., 
Fargo, ND 
 (3.7 miles away)
701-234-6161
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Speaks: English. Dr. Tinguely is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Tinguely is board certified in American Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Tinguely is currently accepting new patients.

Expertise in
47
conditions
Dr. Mahendra K. Gupta
Oncology | Hematology
Expertise in
47
conditions
Dr. Mahendra K. Gupta
Oncology | Hematology
Referral may be required

Sanford Roger Maris Cancer Center

820 Fourth St. N., 
Fargo, ND 
 (3.7 miles away)
701-234-6161
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Speaks: English. Dr. Gupta is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Gupta is board certified in American Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Gupta is currently accepting new patients.

Expertise in
36
conditions
Dr. Radhakrishna R. Vegunta
Oncology | Hematology
Expertise in
36
conditions
Dr. Radhakrishna R. Vegunta
Oncology | Hematology
Referral may be required

Sanford Roger Maris Cancer Center

820 Fourth St. N., 
Fargo, ND 
 (3.7 miles away)
701-234-6161
Languages Spoken:
English, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Speaks: English, Telugu. Dr. Vegunta is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Bone Marrow Aspiration. Dr. Vegunta is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Vegunta is currently accepting new patients.

Frequently Asked Questions about Dr. Sam J. Milanovich

How do I make an appointment with Dr. Sam J. Milanovich?

You can book an appointment with Dr. Sam J. Milanovich by calling their office at 701-234-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sam J. Milanovich a top-rated expert for Reticulohistiocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sam J. Milanovich is classified as an Advanced expert for Reticulohistiocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sam J. Milanovich specialize in?

While Dr. Sam J. Milanovich is a Hematology, they have specific expertise in Reticulohistiocytoma, Histiocytosis, and Langerhans Cell Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sam J. Milanovich participate in research or clinical trials?

Yes. Dr. Sam J. Milanovich has published 11 articles and abstracts on conditions like Reticulohistiocytoma. You can view a list of Dr. Sam J. Milanovich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sam J. Milanovich accept my insurance?

Dr. Sam J. Milanovich accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 701-234-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Milanovich's expertise for a condition
ConditionClose
      View All 37 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile